These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 13933526)

  • 1. [Observations on the subject of clinical experimentation of a new synthetic antianginal compound: N-3'-phenyl-propyl-(2')-1,1-diphenyl-propyl-(3)-amine].
    MATANO F; ROMANO V
    Minerva Med; 1963 Apr; 54():1193-9. PubMed ID: 13933526
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new synthetic substance in the therapy of angina pectoris, N-3'-phenyl-propyl-(2')-1,1-diphenyl-propyl-(3)-amine].
    BAROCELLI C
    Minerva Med; 1963 Apr; 54():1202-6. PubMed ID: 13969419
    [No Abstract]   [Full Text] [Related]  

  • 3. [3'-phenyl-propyl-(2')]-1, 1-diphenyl-propyl-(3)-amine (Segontin).
    MALTEZ JS
    J Med (Oporto); 1963 Jan; 50():189-202. PubMed ID: 13932641
    [No Abstract]   [Full Text] [Related]  

  • 4. [PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE (SEGONTIN) IN TREATMENT OF SYNDROMES DUE TO CORONARY INSUFFICIENCY IN PATIENTS OVER SEVENTY].
    FRANZINI C; TURRI C; MONTEROSSO A
    Minerva Cardioangiol; 1964 Dec; 12():515-27. PubMed ID: 14269033
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental and clinical observations on the action of a new anti-angina drug: 3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine lactate or FPDFPA].
    MIGHELI B; ANSELMINO A; BERT G; ANFOSSI F; BIANCO A; PUPITA F
    Clin Ter; 1963 Mar; 24():530-42. PubMed ID: 13935671
    [No Abstract]   [Full Text] [Related]  

  • 6. [METABOLIC EFFECTS OF PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE IN THE HEALTHY MAN AND IN THE PATIENT WITH ISCHEMIC HEART DISEASE. I. CLINICAL AND EXPERIMENTAL PHARMACOLOGY OF FEDIPRA].
    ZOLI A; BRAT A; GIARDINA A
    Riv Crit Clin Med; 1963 Apr; 63():75-90. PubMed ID: 14277814
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment with phenyl-propyl-diphenyl-propyl-amine (Segontin Hoechst) in coronary disease].
    DOBREANU-ENESCU V; TEODORINI S; HARNAGEA P
    Stud Cercet Med Interna; 1963; 4():243-53. PubMed ID: 14028230
    [No Abstract]   [Full Text] [Related]  

  • 8. [CLINICO-ELECTROCARDIOGRAPHIC OBSERVATIONS ON THE ACTIVITY OF N-(3)-PHENYLPROPYL-(2)-1,1-DIPHENYL-PROPYL-(3)-AMINE (F.P.D.P.A.) IN CORONARY INSUFFICIENCY].
    MENCI S
    Gazz Int Med Chir; 1964 Jan; 68():98-109. PubMed ID: 14123796
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical observations on the use of a new synthetic agent (3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine, Segontin) in coronary insufficiency syndromes].
    CESARI L
    Gazz Int Med Chir; 1962 Sep; 66():1994-2004. PubMed ID: 14019763
    [No Abstract]   [Full Text] [Related]  

  • 10. [CLINICAL TRIALS WITH PHENYL-DIPHENYL-PROPYL-AMINE IN CORONARY INSUFFICIENCY].
    TRILLA SANCHEZ E; BELLONCANEIRO JM; TORNER SOLER M
    Rev Esp Cardiol; 1963 Oct; 16():873-84. PubMed ID: 14117507
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preliminary observations on the therapy of angina pectoris with a new synthetic drug: 3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine].
    GUERRICCHIO G
    Minerva Cardioangiol; 1962 Nov; 10():766-71. PubMed ID: 13951123
    [No Abstract]   [Full Text] [Related]  

  • 12. [METABOLIC EFFECTS OF PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE IN HEALTHY PERSONS AND IN PATIENTS WITH ISCHEMIC HEART DISEASES. II. TECHNICAL METHODS OF RESEARCH AND RESULTS].
    ZOLI A; BRAT A; GIARDINA A
    Riv Crit Clin Med; 1963 Aug; 63():149-73. PubMed ID: 14187838
    [No Abstract]   [Full Text] [Related]  

  • 13. [CONSIDERATIONS ON THE THERAPY OF CORONARY INSUFFICIENCY WITH PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE (FPDPA)].
    RIZZI R; BOZZA G; CESARI A; PASSERELLI A; VANGELISTA A
    Gazz Int Med Chir; 1964 Apr; 68():771-94. PubMed ID: 14159018
    [No Abstract]   [Full Text] [Related]  

  • 14. [METABOLIC EFFECTS OF PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE IN HEALTHY PERSONS AND IN PATIENTS WITH ISCHEMIC HEART DISEASES. 3. CRITICAL EXAMINATION OF THE RESULTS AND CONCLUSIVE CONSIDERATIONS].
    ZOLI A; BRAT A; GIARDINA A
    Riv Crit Clin Med; 1963 Aug; 63():174-98. PubMed ID: 14192243
    [No Abstract]   [Full Text] [Related]  

  • 15. [NEW CLINICO-EXPERIMENTAL CONFIRMATIONS ON THE EFFICACY OF PHENYL-PROPYL-DIPHENYL-PROPYL-AMINE IN CORONARY DISEASES].
    PINACCI U; RIVALI A
    Minerva Cardioangiol; 1965 May; 13():291-8. PubMed ID: 14333361
    [No Abstract]   [Full Text] [Related]  

  • 16. [CATECHOLAMINE EXCRETION AND THE CLINICAL PICTURE IN THE MANAGEMENT OF CARDIAC INFARCTION AND CORONARY INSUFFICIENCY WITH N 3-PHENYLPROPYL -(2) 1, 1-DIPHENYL-PROPYL-(3)-AMINE].
    GAWELLEK F; ECKERT H
    Dtsch Gesundheitsw; 1964 Jul; 19():1339-46. PubMed ID: 14243103
    [No Abstract]   [Full Text] [Related]  

  • 17. [3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine.] (Segontin) in syndromes of coronary insufficiency. Preliminary note].
    DELLA PORTA P; LUCCHINI CR
    Minerva Cardioangiol; 1961 Sep; 9():533-6. PubMed ID: 13885183
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of a preparation with antistenocardiac action, 3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine].
    PRETOLANI E
    Gazz Int Med Chir; 1963 May; 67():1011-21. PubMed ID: 13986080
    [No Abstract]   [Full Text] [Related]  

  • 19. [INVESTIGATION ON THE BEHAVIOR OF 3,3-DIPHENYL-N-(ALPHA-METHYLPHENETHYL)-3-PROPYLAMINE (SEGONTIN) AGAINST THE ACTION OF NORADRENALINE].
    LINDNER E
    Arch Int Pharmacodyn Ther; 1963 Dec; 146():475-84. PubMed ID: 14103284
    [No Abstract]   [Full Text] [Related]  

  • 20. [RESEARCH ON THE ANTIFIBRILLATORY ACTION OF 3,3-DIPHENYL-N-(ALPHA-METHYLPHENETHYL)-3-PROPYLAMINE (SEGONTIN)].
    LINDNER E
    Arch Int Pharmacodyn Ther; 1963 Dec; 146():485-500. PubMed ID: 14103285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.